Joseph F. Standing , 1 , 2 , Martin O. Ongas 3 , 4 , Caroline Ogwang 5 , Nancy Kagwanja 5 , Sheila Murunga 5 , Shalton Mwaringa 5 , Rehema Ali 5 , Neema Mturi 5 , Moline Timbwa 5 , 6 , Christine Manyasi 5 , 6 , Laura Mwalekwa 5 , 7 , Victor L. Bandika 7 , Bernhards Ogutu 3 , 4 , Joseph Waichungo 5 , Karin Kipper 8 , 9 , James A. Berkley 5 , 10 , 11 , for the FLACSAM‐PK Study Group
19 April 2018
Infants and young children with severe acute malnutrition (SAM) are treated with empiric broad‐spectrum antimicrobials. Parenteral ceftriaxone is currently a second‐line agent for invasive infection. Oral metronidazole principally targets small intestinal bacterial overgrowth. Children with SAM may have altered drug absorption, distribution, metabolism, and elimination. Population pharmacokinetics of ceftriaxone and metronidazole were studied, with the aim of recommending optimal dosing. Eighty‐one patients with SAM (aged 2–45 months) provided 234 postdose pharmacokinetic samples for total ceftriaxone, metronidazole, and hydroxymetronidazole. Ceftriaxone protein binding was also measured in 190 of these samples. A three‐compartment model adequately described free ceftriaxone, with a Michaelis–Menten model for concentration and albumin‐dependent protein binding. A one‐compartment model was used for both metronidazole and hydroxymetronidazole, with only 1% of hydroxymetronidazole predicted to be formed during first‐pass. Simulations showed 80 mg/kg once daily of ceftriaxone and 12.5 mg/kg twice daily of metronidazole were sufficient to reach therapeutic targets.